6-Oxo-6-(4-methoxyphenylamino)hexanoic acid | 142326-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-Oxo-6-(4-methoxyphenylamino)hexanoic acid
• 英文别名: 6-(4-methoxyanilino)-6-oxohexanoic acid
• CAS: 142326-15-6
• 化学式: C₁₃H₁₇NO₄
• mdl: MFCD12075118
• 分子量: 251.282
• InChiKey: RQQTZXUOGXFEQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-Oxo-6-(4-methoxyphenylamino)hexanoic acid 、 谷氨酸二甲酯 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以70%的产率得到dimethyl (6-((4-methoxyphenyl)amino)-6-oxohexanoyl)-L-glutamate
  参考文献：
  名称：

  Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model

  摘要：

  Autotaxin (ATX) catalyzes the hydrolysis of lysophosphatidylcholine (LPC) generating the lipid mediator lysophosphatidic acid (LPA). Both ATX and LPA are involved in various pathological inflammatory conditions, including fibrosis and cancer, and have attracted great interest as medicinal targets over the past decade. Thus, the development of novel potent ATX inhibitors is of great importance. We have developed a novel class of ATX inhibitors containing the zinc binding functionality of hydroxamic acid. Such novel hydroxamic acids that incorporate a non-natural delta-amino acid residue exhibit high in vitro inhibitory potency over ATX (IC50 values 50-60 nM). Inhibitor 32, based on delta-norleucine, was tested for its efficacy in a mouse model of pulmonary inflammation and fibrosis induced by bleomycin and exhibited promising efficacy. The novel hydroxamic ATX inhibitors provide excellent tools for the study of the role of the enzyme and could contribute to the development of novel therapeutic agents for the treatment of fibrosis and other chronic inflammatory diseases.

  DOI：

  10.1021/acs.jmedchem.8b00232

文献信息

• Serotonin 5HT.sub.1A agonists
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05189179A1

  公开（公告）日：1993-02-23

  The present invention is directed to a new class of serotonin 5HT.sub.1A agonists.

  本发明涉及一种新型的5HT.sub.1A受体激动剂。
• 1,4 benzodioxin derivatives and their use as serotonin 5HT.sub.1A
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05387604A1

  公开（公告）日：1995-02-07

  The present invention is directed to a new class of serotonin 5HT.sub.1A agonists.

  本发明涉及一种新的类别的血清素5HT.sub.1A激动剂。
• Serotonin 5HT.sub.1A agonistic method
  申请人：Merrell Pharmaceuticals Inc.

  公开号：US05559143A1

  公开（公告）日：1996-09-24

  The present invention is directed to a new class of serotonin 5HT.sub.1A agonists.

  本发明涉及一种新型的5-羟色胺5HT.sub.1A激动剂。
• Serotonin 5HT1A and 5HT1D antagonists
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0478954A1

  公开（公告）日：1992-04-08

  The present invention is directed to a new class of serotonin 5HT1A agonists and pharmaceutical compositions containing them.

  本发明涉及一类新的血清素 5HT1A 激动剂和含有它们的药物组合物。
• Serotonin 5HT1A and 5HT1D agonists
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0478954B1

  公开（公告）日：2000-10-18